OGIVRI® (trastuzumab-dkst) – FDA approved Viatris biosimilar

The first FDA-approved biosimilar trastuzumab
and the first with OS at 36 months^1,2,12

Primary endpoint met: equivalent ORR at 24 weeks
compared with reference trastuzumab²

OGIVRI^® has
an established
Q-code:
Q5114

The first FDA-approved biosimilar trastuzumab
and the first with OS at 36 months^1,2,12

Primary endpoint met: equivalent ORR at 24 weeks
compared with reference trastuzumab²

OGIVRI^® has
an established
Q-code:
Q5114

Register now

Connect with us for news and updates related to OGIVRI^® (trastuzumab-dkst) injection.

*All fields required

First Name *

Please enter a First Name.

Last Name*

Please enter a Last Name.

Email*

Please enter a valid email address.

Confirm Email Address*

Please enter a valid email address.

Email and Confirm Email must Match

Specialty*

Please choose a Specialty

Zip Code*

Please enter a Zip Code.